Format

Send to

Choose Destination
Vaccine. 2014 Nov 20;32(49):6597-600. doi: 10.1016/j.vaccine.2014.09.068. Epub 2014 Oct 11.

Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.

Author information

1
Institut Pasteur de Paris, Unité PTMMH, 25-28 rue du Dr Roux, F-75015 Paris, France; Centre National de la Recherche Scientifique, CNRS, URA3012 Paris, France.
2
Institut Pasteur de Paris, Unité PTMMH, 25-28 rue du Dr Roux, F-75015 Paris, France; Centre National de la Recherche Scientifique, CNRS, URA3012 Paris, France. Electronic address: nicole.guiso@pasteur.fr.

Abstract

Bordetella pertussis is the etiologic agent of whooping cough and has been the target of vaccination for over fifty years. The latest strategies include the use of acellular pertussis vaccines that induce specific immunity against few virulence factors amongst which pertactin is included in three and five component acellular pertussis vaccines. Recently, it has been reported that B. pertussis clinical isolates loose the production of this adhesin in regions reaching high vaccine coverage with vaccines targeting this virulence factor. We here demonstrate that isolates not producing pertactin are capable of sustaining longer infection as compared to pertactin producing isolates in an in vivo model of acellular pertussis immunization. Loosing pertactin production might thus provide a selective advantage to these isolates in this background, which could account for the upraise in prevalence of these pertactin deficient isolates in the population.

KEYWORDS:

Bordetella pertussis; Mice colonization; Pertactin deficiency; Whooping cough

PMID:
25312274
DOI:
10.1016/j.vaccine.2014.09.068
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center